Question 1

What is RETIFANLIMAB-DLWR used for?

Accepted Answer

RETIFANLIMAB-DLWR (brand name ZYNYZ) is a Other indicated for in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ZYNYZ, as a single agent.

Question 2

How does RETIFANLIMAB-DLWR work?

Accepted Answer

RETIFANLIMAB-DLWR works through the following mechanism: 12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Retifanlimab-dlwr binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD‑L2, and potentiates T-cell activity..

Question 3

What are the most common side effects of RETIFANLIMAB-DLWR?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for RETIFANLIMAB-DLWR. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is RETIFANLIMAB-DLWR the same as ZYNYZ?

Accepted Answer

ZYNYZ is a brand name for RETIFANLIMAB-DLWR. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

RETIFANLIMAB-DLWR

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations